PharmaEssentia Corporation, a global biopharmaceutical company headquartered in Taiwan, will invest approximately $46 million to establish a new, wholly owned manufacturing subsidiary in Puerto Rico.

The planned investment supports the company’s global manufacturing expansion strategy and is intended to serve as a future manufacturing center for the U.S. market and long-term global demand for BESREMi (ropeginterferon alfa-2b).

The investment reflects sustained global demand growth for BESREMi, particularly in the United States, as well as the potential additional demand growth from regulatory approvals of BESREMi for new uses.

The planned manufacturing facility is expected to provide several long-term strategic benefits for PharmaEssentia, including enhanced supply security, increased operational flexibility, improved cost efficiency, and scalable manufacturing capacity to support future growth.

“Expanding manufacturing capacity outside Taiwan is a core strategic priority for PharmaEssentia as we continue to strengthen supply resilience, scalability, and geographic diversification,” said Ko-Chung Lin, Ph.D., Founder and CEO of PharmaEssentia. “We are proud to take this important step toward establishing U.S.-based manufacturing, with Puerto Rico serving as a future center for the U.S. market. This investment underscores our long-term commitment to reliably serving patients worldwide as demand for BESREMi continues to grow.”

More Puerto Rico News

Eli Lilly and Company recently announced plans to invest more than $1.2 billion to expand and modernize its Lilly del Caribe manufacturing site in Carolina, Puerto Rico.